The studies conducted by our research team on the interaction between CTLA-4 and CD86 in the course of CLL in the context of EBV reactivation, as well as the currently presented studies, show how important this pathway is in inhibiting the anti-cancer response. The gene discussed is CD86; the disease is cancer.